Crystal Medicines Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.00 Cr
as on 16-11-2024
- Company Age 20 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 13.41 Cr
as on 16-11-2024
- Satisfied Charges ₹ 9.10 Cr
as on 16-11-2024
- Revenue 18.04%
(FY 2023)
- Profit -2.82%
(FY 2023)
- Ebitda 2.68%
(FY 2023)
- Net Worth 11.01%
(FY 2023)
- Total Assets -11.54%
(FY 2023)
About Crystal Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹13.41 Cr. The company has closed loans amounting to ₹9.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Hussain Patanwala, Samad Patanwala, Rashida Patanwala, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PTC148426
- Company No.
148426
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Crystal Medicines?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abdul Shaikh  | Director | 06-Sep-2004 | Current |
| Hussain Patanwala | Director | 06-Sep-2004 | Current |
| Samad Patanwala | Director | 21-Dec-2011 | Current |
| Rashida Patanwala | Director | 01-Aug-2012 | Current |
| Fahad Patanwala | Director | 01-Oct-2020 | Current |
Financial Performance of Crystal Medicines.
Crystal Medicines Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.04% increase. The company also saw a slight decrease in profitability, with a 2.82% decrease in profit. The company's net worth Soared by an impressive increase of 11.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crystal Medicines?
In 2023, Crystal Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Aug 2020 | ₹1.41 Cr | Open |
Others Creation Date: 30 Jan 2018 | ₹12.00 Cr | Open |
Bombay Mercantile Co-Operative Bank Limited Creation Date: 18 Mar 2008 | ₹7.50 Cr | Satisfied |
How Many Employees Work at Crystal Medicines?
Crystal Medicines has a workforce of 12 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crystal Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crystal Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
